Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Tiratricol. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRB known ✓ | P10828 | 10/20 | 0.77 |
| ▸ | THRA known ✓ | P10827 | 8/20 | 0.77 |
| ▸ | PCNA | P12004 | 9/20 | 0.77 |
| ▸ | LMNA | P02545 | 4/20 | 0.77 |
| ▸ | POLB | P06746 | 3/20 | 0.77 |
| ▸ | HIF1A | Q16665 | 3/20 | 0.77 |
| ▸ | PPARG | P37231 | 3/20 | 0.77 |
| ▸ | HPGD | P15428 | 2/20 | 0.77 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.77 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.77 |
| ▸ | ABCB11 | O95342 | 2/20 | 0.77 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.77 |
| ▸ | GABRA2 | P47869 | 2/20 | 0.77 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.77 |
| ▸ | RXRA | P19793 | 2/20 | 0.77 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.77 |
| ▸ | PGR | P06401 | 1/20 | 0.77 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.77 |
| ▸ | HTR1A | P08908 | 1/20 | 0.77 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.77 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Tiratricol SCHEMBL25149 | 0.87 | THRB (1.00) | THRBPCNATHRALMNAPOLB | |
| Tiratricol SCHEMBL743426 | 0.87 | THRB (1.00) | THRBPCNATHRALMNAPOLB | |
| Tiratricol SCHEMBL30161572 | 0.87 | THRB (1.00) | THRBPCNATHRALMNAPOLB | |
| Tiratricol SCHEMBL10701956 | 0.86 | THRB (0.97) | THRBPCNATHRALMNAPOLB | |
| Tiratricol SCHEMBL2671904 | 0.86 | THRB (0.97) | THRBPCNATHRALMNAPOLB | |
| Tiratricol SCHEMBL8660328 | 0.86 | THRB (0.97) | THRBPCNATHRALMNAPOLB | |
| SCHEMBL14485277 | 0.86 | THRB (0.77) | THRBPCNATHRALMNAPOLB | |
| SCHEMBL16124484 | 0.86 | THRB (0.77) | THRBPCNATHRALMNAPOLB | |
| SCHEMBL16124436 | 0.82 | PCNA (1.00) | THRBPCNATHRALMNAPOLB | |
| SCHEMBL16124426 | 0.82 | PCNA (1.00) | THRBPCNATHRALMNAPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260102359-A1 | COMBINATION TREATMENT OF DERMAL AND TRANSDERMAL FIBROTIC DISEASES, DISORDERS AND ASSOCIATED PAIN AND INFLAMMATION | ERESINA LLC (US) | 2026-04-16 | — | — | US | disclosed |
| US-12419870-B2 | Compositions and methods for immune cell modulation in adoptive immunotherapies | FATE THERAPEUTICS, INC. (US) | 2025-09-23 | — | — | US | disclosed |
| US-20250215396-A1 | COMPOSITIONS AND METHODS FOR IMMUNE CELL MODULATION IN ADOPTIVE IMMUNOTHERAPIES | FATE THERAPEUTICS, INC. | 2025-07-03 | — | — | US | disclosed |
| US-12281329-B2 | Compositions and methods for immune cell modulation in adoptive immunotherapies | FATE THERAPEUTICS, INC. (US) | 2025-04-22 | — | — | US | disclosed |
| US-20240263135-A1 | COMPOSITIONS AND METHODS FOR IMMUNE CELL MODULATION IN ADOPTIVE IMMUNOTHERAPIES | FATE THERAPEUTICS, INC. | 2024-08-08 | — | — | US | disclosed |
| CN-118252830-A | Use of compounds in the preparation of a medicament for preventing, treating, alleviating or alleviating fibrotic diseases | 厦门大学 | 2024-06-28 | — | — | CN | disclosed |
| US-11932870-B2 | Compositions and methods for immune cell modulation in adoptive immunotherapies | FATE THERAPEUTICS, INC. | 2024-03-19 | — | — | US | disclosed |
| US-20230082555-A1 | Composition for Medium | KATAOKA CORPORATION (JP) | 2023-03-16 | — | — | US | disclosed |
| US-20220401487-A1 | COMPOSITIONS AND METHODS FOR IMMUNE CELL MODULATION IN ADOPTIVE IMMUNOTHERAPIES | FATE THERAPEUTICS, INC. | 2022-12-22 | — | — | US | disclosed |
| EP-4083194-A1 | COMPOSITION FOR MEDIUM | Kataoka Corporation (JP) | 2022-11-02 | — | — | EP | disclosed |
| US-20190282618-A1 | COMPOSITIONS AND METHODS FOR IMMUNE CELL MODULATION IN ADOPTIVE IMMUNOTHERAPIES | FATE THERAPEUTICS, INC. | 2019-09-19 | — | — | US | disclosed |
| US-20190125795-A1 | COMPOSITIONS AND METHODS FOR IMMUNE CELL MODULATION IN ADOPTIVE IMMUNOTHERAPIES | FATE THERAPEUTICS, INC. | 2019-05-02 | — | — | US | disclosed |
| EP-2846788-A1 | USE OF COMPOUNDS FOR THE TREATMENT OF PAIN | Akron Molecules AG (AT) | 2015-03-18 | — | — | EP | disclosed |
| WO-2013167743-A1 | USE OF COMPOUNDS FOR THE TREATMENT OF PAIN | AKRON MOLECULES GMBH (AT) | 2013-11-14 | — | — | WO | disclosed |
| US-7927613-B2 | Pharmaceutical co-crystal compositions | UNIVERSITY OF SOUTH FLORIDA (US) | 2011-04-19 | — | — | US | disclosed |
| US-7790905-B2 | Pharmaceutical propylene glycol solvate compositions | MCNEIL-PPC, INC. (US) | 2010-09-07 | — | — | US | disclosed |
| US-20040234592-A1 | Mixture containing thyroid hormone , ethanolamine and emulsifier | KARO BIO AB (SE) | 2004-11-25 | — | — | US | disclosed |
| CN-1518469-A | Dermatological preparations | �����ɷ� | 2004-08-04 | — | — | CN | disclosed |
| EP-1404413-A2 | DERMATOLOGICAL FORMULATIONS | KARO BIO AB (SE) | 2004-04-07 | — | — | EP | disclosed |
| WO-2002089917-A2 | DERMATOLOGICAL FORMULATIONS | KARO BIO AB (SE) | 2002-11-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260102359-A1 | COMBINATION TREATMENT OF DERMAL AND TRANSDERMAL FIBROTIC DISEASES, DISORDERS AND ASSOCIATED PAIN AND INFLAMMATION | COL2A1, COLGALT1, PLOD3 | THRB 3769/4885THRA 4139/4885PCNA 318/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.